Comparative Pharmacology
Head-to-head clinical analysis: BEVESPI AEROSPHERE versus ICOTYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEVESPI AEROSPHERE versus ICOTYDE.
BEVESPI AEROSPHERE vs ICOTYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BEVESPI AEROSPHERE is a combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA). Glycopyrrolate inhibits acetylcholine at M3 muscarinic receptors in bronchial smooth muscle, leading to bronchodilation. Formoterol stimulates beta2-adrenergic receptors, increasing cyclic AMP and relaxing bronchial smooth muscle.
ICOTYDE (trifluridine/tipiracil) is a combination of trifluridine, a thymidine-based nucleoside analog that incorporates into DNA and inhibits cell proliferation, and tipiracil, a thymidine phosphorylase inhibitor that increases the systemic exposure of trifluridine by inhibiting its degradation.
Two inhalations (glycopyrrolate 18 mcg / formoterol fumarate 9.6 mcg per inhalation) twice daily, administered orally via inhalation.
Intravenous: 1000 mg administered over 90 minutes on days 1 and 15 of a 28-day cycle.
None Documented
None Documented
Glycopyrrolate: terminal elimination half-life 3.2 to 4.1 hours after inhalation; formoterol: terminal elimination half-life approximately 10 hours after inhalation. Context: Steady-state achieved within 2 to 3 days.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged in renal impairment.
Renal: 15% to 30% as unchanged drug after intravenous administration for glycopyrrolate; fecal: 65% to 80% as unchanged drug after oral administration for glycopyrrolate. For formoterol, renal: 10% to 20% as unchanged drug; bile/fecal: 60% to 70%.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing the remaining 30%.
Category C
Category C
LAMA/LABA Combination
ICS/LABA Combination